CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed a non-exclusive license agreement with a leading European veterinary pharmaceutical company for use of its proprietary CAPÂ®Go cells in the development, production and commercialization of two difficult to express recombinant proteins in the field of veterinary vaccines.
Under the terms of the agreement, CEVEC provides its expertise in cell line development and in the expression of difficult-to-produce recombinant proteins utilizing its CAPÂ®Go platform. Furthermore, the company has granted its contracting partner rights to use CEVEC’s proprietary CAPÂ®Go technology for the development, production and commercialization of certain protein products for the vaccination of livestock animals. The license agreement was the result of extensive previous studies delivering conclusive data on the effective and cost-efficient production of the proteins with the CAPÂ®Go platform.
“We are very pleased to work with a leading company in animal health on this exciting project,” commented Nico Scheer, Chief Business Officer of CEVEC. “The fact that CAPÂ®Go cells were selected by our partner for the production of two proteins is a significant endorsement of our technology. The expression of those proteins turned out to be extremely difficult in other systems. With our CAPÂ®Go technology, we are addressing an increasing need in the pharmaceutical, biotechnology and also veterinary industries for the efficient manufacturing of difficult-to-express therapeutic proteins with tailor-made glycosylation patterns for significantly improved physicochemical and pharmacological properties.”